Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040

Published: Thursday, August 08, 2013
Last Updated: Thursday, August 08, 2013
Bookmark and Share
Results published in the British Journal of Hematology.

BioLineRx has announced that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

The findings were published in the British Journal of Hematology, a leading journal in the field. The study, headed by Prof. Amnon Peled from the Goldyne Savad Institute of Gene Therapy - Hadassah University Hospital, assessed the effect of repeated doses of BL-8040 on healthy and chemotherapy-induced thrombocytopenic mice.

The results show that repeated administration of BL-8040 significantly increased the number of megakaryocytes (cells that produce platelets) within the bone marrow; this was associated with increased production and increased levels of platelets in the blood circulation, in both the healthy and chemotherapy induced-thrombocytopenic mice.

In addition, BL-8040 increased the number of hematopoietic progenitor cells within the bone marrow and in the blood. These cells are important for generating not only platelets but the whole gamut of red and white blood cells.

In addition, BL-8040 significantly reduced the severity and duration of chemotherapy-induced thrombocytopenia and cytopenia.

"We are currently developing BL-8040 for acute myeloid leukemia (AML), and a Phase 2 clinical trial for this indication is underway at the MD Anderson Cancer Center in Houston and other leading centers in the U.S. and Israel," said Kinneret Savitsky, Ph.D., CEO of BioLineRx.

Savitsky continued, "We have previously stated that we intend to pursue additional hematological indications for this promising asset. The results of this study, which provide evidence for the possible therapeutic use of BL-8040 for modulating platelet numbers in thrombocytopenic conditions, offer new possibilities which we may choose to explore further in pre-clinical and early-stage clinical trials. In addition, the ability of this novel drug to reduce thrombocytopenia, a frequent side effect of chemotherapy, makes BL-8040 even more appealing as a candidate for blood cancer treatment."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment
Study is first of three additional clinical studies for BL-8040 platform expected to commence during 2015.
Tuesday, August 18, 2015
Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment
BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.
Tuesday, March 03, 2015
BioLineRx Presents Multi-Year Clinical Development Plan for BL-8040
Clinical trials in three additional indications for BL-8040 to be initiated in 2015.
Saturday, December 13, 2014
BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients
Results in this additional indication for BL-8040 presented at Society of Hematologic Oncology Annual Meeting.
Saturday, September 20, 2014
BioLineRx Doses First Patient for BL-8040’s Second Indication
Results from Phase 1 trial expected by end of 2014 or early 2015.
Friday, September 05, 2014
BioLineRx Announces Investigator-Initiated Study for Novel CML Treatment
Phase 1/2 study will assess effect of BL-8040 in combination with standard therapy.
Saturday, April 12, 2014
BioLineRx Announces Positive Preclinical Results for Novel Treatment for CML
BL-8040 study published in Molecular Cancer Therapeutics.
Thursday, February 13, 2014
BioLineRx Announces Promising Initial Phase 2 Results of AML Treatment
Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis).
Friday, December 20, 2013
BioLineRx Reports Publication of Positive Phase 1/2 Results in Stem Cell Mobilization
Additional clinical trial in stem cell mobilization expected to commence in H1 2014.
Friday, November 22, 2013
BioLineRx Enrolls First Patient in Phase 2 Clinical Trial for BL-8040
Partial results expected in Q4 2013.
Friday, June 07, 2013
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial for BL-8040
Final results expected in H2 2014.
Thursday, April 11, 2013
BioLineRx In-Licenses BL-8040 for the Treatment of AML
Phase II clinical trials are expected to commence in H1 2013.
Wednesday, January 16, 2013
Scientific News
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos